Literature DB >> 25123977

Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication.

Vincenzo Marotta1, Carolina Di Somma, Manila Rubino, Concetta Sciammarella, Michela Del Prete, Francesca Marciello, Valeria Ramundo, Luisa Circelli, Pasqualina Buonomano, Roberta Modica, Mario Vitale, Annamaria Colao, Antongiulio Faggiano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25123977     DOI： 10.1007/s12020-014-0381-0

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  18 in total

1.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

Review 2.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

3.  A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.

Authors:  S J Silverberg; E Shane; T P Jacobs; E Siris; J P Bilezikian
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

Review 4.  Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features.

Authors:  J P Bilezikian; M L Brandi; M Rubin; S J Silverberg
Journal:  J Intern Med       Date:  2005-01       Impact factor: 8.989

5.  Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.

Authors:  Munro Peacock; J P Bilezikian; M A Bolognese; Michael Borofsky; Simona Scumpia; L R Sterling; Sunfa Cheng; Dolores Shoback
Journal:  J Clin Endocrinol Metab       Date:  2010-10-13       Impact factor: 5.958

Review 6.  Cinacalcet hydrochloride for the treatment of hyperparathyroidism.

Authors:  Nicolas Verheyen; Stefan Pilz; Kathrin Eller; Katharina Kienreich; Astrid Fahrleitner-Pammer; Burkert Pieske; Eberhard Ritz; Andreas Tomaschitz
Journal:  Expert Opin Pharmacother       Date:  2013-03-04       Impact factor: 3.889

7.  Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.

Authors:  Aliya A Khan; John P Bilezikian; Annie W C Kung; Mustafa M Ahmed; Sacha J Dubois; Andrew Y Y Ho; Debra Schussheim; Mishaela R Rubin; Atif M Shaikh; Shonni J Silverberg; Timothy I Standish; Zareen Syed; Zeba A Syed
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

8.  The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.

Authors:  Mishaela R Rubin; John P Bilezikian; Donald J McMahon; Thomas Jacobs; Elizabeth Shane; Ethel Siris; Julia Udesky; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2008-06-10       Impact factor: 5.958

9.  Cinacalcet reduces the set point of the PTH-calcium curve.

Authors:  Casimiro Valle; Mariano Rodriguez; Rafael Santamaría; Yolanda Almaden; Maria E Rodriguez; Sagrario Cañadillas; Alejandro Martin-Malo; Pedro Aljama
Journal:  J Am Soc Nephrol       Date:  2008-07-16       Impact factor: 10.121

Review 10.  Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

Authors:  R Eastell; A Arnold; M L Brandi; E M Brown; P D'Amour; D A Hanley; D Sudhaker Rao; M R Rubin; D Goltzman; S J Silverberg; S J Marx; M Peacock; L Mosekilde; R Bouillon; E M Lewiecki
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958
View more
  6 in total

Review 1.  The calcium-sensing receptor in bone--mechanistic and therapeutic insights.

Authors:  David Goltzman; Geoffrey N Hendy
Journal:  Nat Rev Endocrinol       Date:  2015-03-10       Impact factor: 43.330

2.  Recurrent primary hyperparathyroidism due to Type 1 parathyromatosis.

Authors:  Monica Jain; David L Krasne; Frederick R Singer; Armando E Giuliano
Journal:  Endocrine       Date:  2016-10-14       Impact factor: 3.633

Review 3.  Parathyroid Disease in Pregnancy and Lactation: A Narrative Review of the Literature.

Authors:  Elena Tsourdi; Athanasios D Anastasilakis
Journal:  Biomedicines       Date:  2021-04-26

Review 4.  The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies.

Authors:  Manju Chandran; John P Bilezikian; Joel Lau; Reshma Rajeev; Samantha Peiling Yang; Miny Samuel; Rajeev Parameswaran
Journal:  Rev Endocr Metab Disord       Date:  2022-01-18       Impact factor: 9.306

Review 5.  Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review.

Authors:  Julius Simoni Leere; Jesper Karmisholt; Maciej Robaczyk; Peter Vestergaard
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-20       Impact factor: 5.555

6.  Cinacalcet and primary hyperparathyroidism: systematic review and meta regression.

Authors:  Cheng Han Ng; Yip Han Chin; Marcus Hon Qin Tan; Jun Xuan Ng; Samantha Peiling Yang; Jolene Jiayu Kiew; Chin Meng Khoo
Journal:  Endocr Connect       Date:  2020-07       Impact factor: 3.335
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.